Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | SVP/Chief Comm Off, Alks Inc | March 01, 2018 | March 05, 2018 |
| Indivior Pharmaceuticals, Inc.INDV · Entity 4040 | Director | May 13, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date March 01, 2018 · Filed March 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 51,065 |
Ending reported balance
After 2018-03-03 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-03-01 · Exercise / conversion · Acquired 5,250 · Balance 51,837 Row 2 · 2018-03-01 · Tax withholding · Disposed 2,334 · Balance 49,503 Row 3 · 2018-03-03 · Exercise / conversion · Acquired 2,813 · Balance 52,316 Row 4 · 2018-03-03 · Tax withholding · Disposed 1,251 · Balance 51,065 |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 10,500 |
Reported balance
After 2018-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-01 · Exercise / conversion · Disposed 5,250 · Balance 10,500 F1: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-03-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-03-03 · Exercise / conversion · Disposed 2,813 · Balance 0 F2: This RSU award is fully vested in accordance with its terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017.
F2: This RSU award is fully vested in accordance with its terms.
Indivior Pharmaceuticals, Inc.
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,087 |
Reported balance
After 2026-05-13 transaction · row 1
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 6,518 · Balance 27,087 F1: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 12,631 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.87 · Expires 2026-09-12 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.16 · Expires 2027-06-21 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.14 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.74 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.88 · Expires 2030-06-09 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.22 · Expires 2031-06-23 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2017 Filed Feb 21, 2017 22:56 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $54.57 | $0.00 |
DisclosureSEC source: 0001127602-17-007479 · form4.xml · derivative · entry 2 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2027-02-17 F2 · derivative.exercise_date: Shares subject to the stock option award vest in four equal annual installments commencing on 2/17/18. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 22:56 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 12,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007479 · form4.xml · derivative · entry 1 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Ordinary Shares · 12,000 shares Expires not disclosed F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 22:08 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 547 | $0.00 Strike: $17.30 | $0.00 |
DisclosureSEC source: 0001127602-17-001449 · form4.xml · derivative · entry 3 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,660 Underlying: Ordinary Shares · 547 shares Expires 2022-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 22:08 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 547 | $60.27 | $32,967.69 |
DisclosureSEC source: 0001127602-17-001449 · form4.xml · nonDerivative · entry 2 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,115 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 22:08 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 547 | $17.30 | $9,463.10 |
DisclosureSEC source: 0001127602-17-001449 · form4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 06, 2017 Filed Jan 7, 2017 00:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,653 | $0.00 Strike: $17.30 | $0.00 |
DisclosureSEC source: 0001127602-17-001311 · form4.xml · derivative · entry 9 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,207 Underlying: Ordinary Shares · 6,653 shares Expires 2022-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| January 06, 2017 Filed Jan 7, 2017 00:32 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 6,653 | $60.07 | $399,643.05 |
DisclosureSEC source: 0001127602-17-001311 · form4.xml · nonDerivative · entry 6 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,115 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.41. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 06, 2017 Filed Jan 7, 2017 00:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,653 | $17.30 | $115,096.90 |
DisclosureSEC source: 0001127602-17-001311 · form4.xml · nonDerivative · entry 5 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 05, 2017 Filed Jan 7, 2017 00:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 300 | $0.00 Strike: $17.30 | $0.00 |
DisclosureSEC source: 0001127602-17-001311 · form4.xml · derivative · entry 8 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,860 Underlying: Ordinary Shares · 300 shares Expires 2022-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| January 05, 2017 Filed Jan 7, 2017 00:32 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 300 | $60.09 | $18,025.98 |
DisclosureSEC source: 0001127602-17-001311 · form4.xml · nonDerivative · entry 4 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,115 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 05, 2017 Filed Jan 7, 2017 00:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 300 | $17.30 | $5,190.00 |
DisclosureSEC source: 0001127602-17-001311 · form4.xml · nonDerivative · entry 3 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 04, 2017 Filed Jan 7, 2017 00:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $17.30 | $0.00 |
DisclosureSEC source: 0001127602-17-001311 · form4.xml · derivative · entry 7 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,160 Underlying: Ordinary Shares · 2,500 shares Expires 2022-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| January 04, 2017 Filed Jan 7, 2017 00:32 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 2,500 | $60.01 | $150,017.50 |
DisclosureSEC source: 0001127602-17-001311 · form4.xml · nonDerivative · entry 2 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,115 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 04, 2017 Filed Jan 7, 2017 00:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 2,500 | $17.30 | $43,250.00 |
DisclosureSEC source: 0001127602-17-001311 · form4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 22:49 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,780 | $0.00 Strike: $17.30 | $0.00 |
DisclosureSEC source: 0001127602-16-067025 · form4.xml · derivative · entry 3 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,660 Underlying: Ordinary Shares · 5,780 shares Expires 2022-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 22:49 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,692 | $59.07 | $99,946.44 |
DisclosureSEC source: 0001127602-16-067025 · form4.xml · nonDerivative · entry 2 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,115 F2 · kind: This stock swap was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 22:49 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,780 | $17.30 | $99,994.00 |
DisclosureSEC source: 0001127602-16-067025 · form4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 01:15 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-064475 · form4.xml · derivative · entry 3 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit represented a contingent right to receive one ordinary share of Alkermes plc. F2 · derivative.exercise_date: This performance restricted stock unit, which was granted to the reporting person on March 3, 2014, is fully vested in accordance with its terms. F2 · derivative.expiration_date: This performance restricted stock unit, which was granted to the reporting person on March 3, 2014, is fully vested in accordance with its terms. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 01:15 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,623 | $46.43 | $75,355.89 |
DisclosureSEC source: 0001127602-16-064475 · form4.xml · nonDerivative · entry 2 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,027 Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 01:15 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-064475 · form4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2016 Filed Sep 14, 2016 20:20 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $15.87 | $0.00 |
DisclosureSEC source: 0001209191-16-141402 · doc4.xml · derivative · entry 1 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-09-12 F1 · derivative.exercise_date: One-third of the shares subject to the option will vest on September 13, 2017 and the balance of the shares will vest in a series of 24 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.